Nektar Therapeutics Net Income
| NKTR Stock | USD 71.33 0.33 0.46% |
As of the 14th of February 2026, Nektar Therapeutics secures the Mean Deviation of 4.64, downside deviation of 5.13, and Risk Adjusted Performance of 0.0677. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nektar Therapeutics, as well as the relationship between them. Please verify Nektar Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Nektar Therapeutics is priced some-what accurately, providing market reflects its recent price of 71.33 per share. Given that Nektar Therapeutics has jensen alpha of 0.5439, we recommend you to check Nektar Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.
Nektar Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 20.2035 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -107.1 M | -112.4 M | |
| Net Loss | -107.1 M | -112.4 M | |
| Net Loss | -331.4 M | -314.8 M | |
| Net Loss | (9.98) | (10.48) | |
| Net Income Per E B T | 0.90 | 0.74 |
Nektar | Net Income | Build AI portfolio with Nektar Stock |
Evaluating Nektar Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Nektar Therapeutics's fundamental strength.
Latest Nektar Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Nektar Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Nektar Therapeutics financial statement analysis. It represents the amount of money remaining after all of Nektar Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Nektar Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (118.96 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Nektar Net Income Regression Statistics
| Arithmetic Mean | (151,104,944) | |
| Geometric Mean | 152,512,080 | |
| Coefficient Of Variation | (174.18) | |
| Mean Deviation | 156,676,523 | |
| Median | (133,978,000) | |
| Standard Deviation | 263,196,248 | |
| Sample Variance | 69272.3T | |
| Range | 1.2B | |
| R-Value | (0.21) | |
| Mean Square Error | 70680.4T | |
| R-Squared | 0.04 | |
| Significance | 0.42 | |
| Slope | (10,863,528) | |
| Total Sum of Squares | 1108356.2T |
Nektar Net Income History
Other Fundumenentals of Nektar Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Nektar Therapeutics Net Income component correlations
Nektar Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Nektar Therapeutics is extremely important. It helps to project a fair market value of Nektar Stock properly, considering its historical fundamentals such as Net Income. Since Nektar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nektar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nektar Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Pharmaceuticals industry sustain growth momentum? Does Nektar have expansion opportunities? Factors like these will boost the valuation of Nektar Therapeutics. Anticipated expansion of Nektar directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Nektar Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (9.83) | Revenue Per Share | Quarterly Revenue Growth (0.51) | Return On Assets | Return On Equity |
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Nektar Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nektar Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Nektar Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Nektar Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nektar Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nektar Therapeutics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Nektar Therapeutics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Nektar Therapeutics or generate 0.0% return on investment in Nektar Therapeutics over 90 days. Nektar Therapeutics is related to or competes with Inhibrx Biosciences, ATAI Life, Enliven Therapeutics, Syndax Pharmaceuticals, Oric Pharmaceuticals, Relay Therapeutics, and Xencor. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medi... More
Nektar Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nektar Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nektar Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.13 | |||
| Information Ratio | 0.0641 | |||
| Maximum Drawdown | 44.06 | |||
| Value At Risk | (7.77) | |||
| Potential Upside | 8.03 |
Nektar Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nektar Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nektar Therapeutics' standard deviation. In reality, there are many statistical measures that can use Nektar Therapeutics historical prices to predict the future Nektar Therapeutics' volatility.| Risk Adjusted Performance | 0.0677 | |||
| Jensen Alpha | 0.5439 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.1012 | |||
| Treynor Ratio | 0.988 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nektar Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nektar Therapeutics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0677 | |||
| Market Risk Adjusted Performance | 0.998 | |||
| Mean Deviation | 4.64 | |||
| Semi Deviation | 4.83 | |||
| Downside Deviation | 5.13 | |||
| Coefficient Of Variation | 1374.99 | |||
| Standard Deviation | 8.1 | |||
| Variance | 65.58 | |||
| Information Ratio | 0.0641 | |||
| Jensen Alpha | 0.5439 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.1012 | |||
| Treynor Ratio | 0.988 | |||
| Maximum Drawdown | 44.06 | |||
| Value At Risk | (7.77) | |||
| Potential Upside | 8.03 | |||
| Downside Variance | 26.29 | |||
| Semi Variance | 23.37 | |||
| Expected Short fall | (5.21) | |||
| Skewness | 3.85 | |||
| Kurtosis | 23.06 |
Nektar Therapeutics Backtested Returns
Nektar Therapeutics appears to be very steady, given 3 months investment horizon. Nektar Therapeutics has Sharpe Ratio of 0.0701, which conveys that the firm had a 0.0701 % return per unit of risk over the last 3 months. By analyzing Nektar Therapeutics' technical indicators, you can evaluate if the expected return of 0.58% is justified by implied risk. Please exercise Nektar Therapeutics' Mean Deviation of 4.64, downside deviation of 5.13, and Risk Adjusted Performance of 0.0677 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Nektar Therapeutics holds a performance score of 5. The company secures a Beta (Market Risk) of 0.59, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Nektar Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Nektar Therapeutics is expected to be smaller as well. Please check Nektar Therapeutics' maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Nektar Therapeutics' current price movements will revert.
Auto-correlation | -0.48 |
Modest reverse predictability
Nektar Therapeutics has modest reverse predictability. Overlapping area represents the amount of predictability between Nektar Therapeutics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nektar Therapeutics price movement. The serial correlation of -0.48 indicates that about 48.0% of current Nektar Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.48 | |
| Spearman Rank Test | 0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 98.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Nektar Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Nektar Therapeutics reported net income of (118.96 Million). This is 134.86% lower than that of the Pharmaceuticals sector and 269.83% lower than that of the Health Care industry. The net income for all United States stocks is 120.83% higher than that of the company.
Nektar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nektar Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nektar Therapeutics could also be used in its relative valuation, which is a method of valuing Nektar Therapeutics by comparing valuation metrics of similar companies.Nektar Therapeutics is currently under evaluation in net income category among its peers.
Nektar Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nektar Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nektar Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Nektar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Nektar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Nektar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nektar Therapeutics' value.| Shares | Susquehanna International Group, Llp | 2025-06-30 | 221.9 K | Ubs Group Ag | 2025-06-30 | 201.4 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 148.2 K | 22nw, Lp | 2025-06-30 | 146.1 K | Geode Capital Management, Llc | 2025-06-30 | 132.4 K | Jain Global Llc | 2025-06-30 | 128.8 K | Boxer Capital Management, Llc | 2025-06-30 | 125 K | Armistice Capital, Llc | 2025-06-30 | 124 K | Eversept Partners, Llc | 2025-06-30 | 115 K | Altium Capital Management, Lp | 2025-03-31 | 1.1 M | Vanguard Group Inc | 2025-06-30 | 729.5 K |
Nektar Fundamentals
| Return On Equity | -1.8 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.93) % | ||||
| Operating Margin | (2.67) % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 20.34 M | ||||
| Shares Owned By Insiders | 0.83 % | ||||
| Shares Owned By Institutions | 81.66 % | ||||
| Number Of Shares Shorted | 3.29 M | ||||
| Price To Earning | 8.02 X | ||||
| Price To Book | 16.96 X | ||||
| Price To Sales | 23.18 X | ||||
| Revenue | 98.43 M | ||||
| Gross Profit | 54.62 M | ||||
| EBITDA | (86.7 M) | ||||
| Net Income | (118.96 M) | ||||
| Cash And Equivalents | 546.39 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 102.56 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 7.14 X | ||||
| Book Value Per Share | 4.33 X | ||||
| Cash Flow From Operations | (175.71 M) | ||||
| Short Ratio | 4.50 X | ||||
| Earnings Per Share | (9.83) X | ||||
| Price To Earnings To Growth | 3.22 X | ||||
| Target Price | 123.43 | ||||
| Number Of Employees | 61 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 1.45 B | ||||
| Total Asset | 303.85 M | ||||
| Retained Earnings | (3.6 B) | ||||
| Working Capital | 199.89 M | ||||
| Current Asset | 350.05 M | ||||
| Current Liabilities | 61.25 M | ||||
| Net Asset | 303.85 M |
About Nektar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nektar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nektar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nektar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Nektar Stock
| 0.67 | KG | Kestrel Group Symbol Change | PairCorr |
Moving against Nektar Stock
| 0.65 | C43 | Cosmo Pharmaceuticals | PairCorr |
| 0.63 | LDZU | ASPEN PHARUNADR 1 | PairCorr |
| 0.63 | TEV | Teva Pharmaceutical | PairCorr |
| 0.62 | MRK | Merck KGaA | PairCorr |
| 0.59 | R9U2 | Green Thumb Industries | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.